# Desmopressin

## Minirin inj 4mcg/1mL \(DDAVP\)

| 藥物代碼 | IDDA |
| :--- | :--- |
| 適應症 | Central Diabetes Insipidus, Primary Nocturnal Enuresis, Renal Concentrating Capacity Test,Symptomatic treatment of nocturia in adults associated with nocturnal polyuria ie, nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease |
| 副作用 | Nausea, abdominal pain, headache, nasal congestion/rhinitis, nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl.Dermatologic: FlushingGastrointestinal: Nausea, Will respond to dosage decreaseNeurologic: Fatigue \(10% \), Headache \(22.5% \) |
| 禁忌 | Habitual & psychogenic polydipsia, syndrome of inappropriate ADH secretion \(SIADH\), known hyponatremia, known or suspected cardiac decompensation & other conditions that require diuretics, moderate & severe renal impairment. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | Desmopressin acetate solution for injection: 4 micrograms is equivalent in antidiuretic activity to 16 international units of vasopressin. One microgram of desmopressin acetate is equivalent to 4 international units of vasopressin Adult Hemophilia A, With factor VIII levels greater than 5%: 0.3 mcg/kg diluted in 50 mL sterile physiological saline, infused IV slowly over 15 to 30 minutes; monitor patient to determine necessity of further doses, tachyphylaxis may occur if given more often than every 48 hours Neurohypophyseal diabetes insipidus: 2 to 4 mcg/day IV or SUBQ in 2 divided doses; comparable antidiuretic dose of the injection is about one-tenth \(1/10\) the intranasal dose von Willebrand disease type 1 \(Mild to Moderate\), With factor VIII levels greater than 5%: 0.3 mcg/kg diluted in 50 mL sterile physiological saline, infused IV slowly over 15 to 30 minutes; monitor patient to determine necessity of further doses, tachyphylaxis may occur if given more often than every 48 hours Pediatric safety and efficacy of desmopressin acetate injection for the treatment of diabetes insipidus have not been established in children less than 12 years of age |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Compatible 哺乳時可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | Infuse over 15-30 min. Adult: IV: 0.3 mcg/kg by slow infusion, Maximum IV dose: 20 mcg. |
| 注意事項 | Adminisration \(Intravenous\) 1.dilute in sterile physiological saline \(diluent\); use 10 mL diluent if patient 10 kg or less; use 50 mL diluent if patient more than 10 kg 2.infuse over 15-30 min 3.give 30 min prior to surgical procedures if need to give preoperatively 4.fluid restriction recommended |

## Minirin Melt 60mcg 凍晶口溶錠

| 藥物代碼 | OMIN6 |
| :--- | :--- |
| 適應症 | 主治尿崩症、夜尿症Central Diabetes Insipidus, Primary Nocturnal Enuresis, Renal Concentrating Capacity Test,Symptomatic treatment of nocturia in adults associated with nocturnal polyuria ie, nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease |
| 副作用 | Nausea, abdominal pain, headache, nasal congestion/rhinitis, nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl.Dermatologic: FlushingGastrointestinal: Nausea, Will respond to dosage decreaseNeurologic: Fatigue \(10% \), Headache \(22.5% \) |
| 禁忌 | Habitual & psychogenic polydipsia, syndrome of inappropriate ADH secretion \(SIADH\), known hyponatremia, known or suspected cardiac decompensation & other conditions that require diuretics, moderate & severe renal impairment. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Central diabetes insipidus Adult & childn Initially 60 mcg tid.Maintenance: 60-120 mcg tid. Primary nocturnal enuresis Patient from 6 yr Initially 120 mcg at bedtime, may be increased up to 240 mcg. Nocturia Adult Initially 60 mcg at bedtime, may be increased up to 120 mcg after 1 wk & subsequently 240 mcg by wkly dose escalations. To be administered sublingually. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Compatible 哺乳時可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

